Evercore ISI Group has initiated coverage on Dexcom Inc (DXCM) with an In-Line rating. This marks the firm's first assessment of the company's investment potential.
Dexcom, headquartered in San Diego, California, specializes in glucose monitoring systems for diabetes management. The company has a market capitalization of $24.3 billion and a P/E ratio of 33.67. Its products include the Dexcom G6 and G7 continuous glucose monitoring systems, designed for both adults and children. Dexcom's innovative technology enables patients to manage their health effectively.
The current share price stands at $62.53. Upcoming earnings are scheduled for July 28, 2026, with an estimated EPS of $0.60 and revenue of $1.3 billion. Analyst ratings like this one provide valuable insights but should be considered alongside company fundamentals and market trends for informed investment decisions.